Goletz TJ - Search Results

1

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.

Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP. Bronte V, et al. Among authors: goletz tj. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3183-8. doi: 10.1073/pnas.94.7.3183. Proc Natl Acad Sci U S A. 1997. PMID: 9096367 Free PMC article.

2

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.

Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. Overwijk WW, et al. Among authors: goletz tj. J Exp Med. 1998 Jul 20;188(2):277-86. doi: 10.1084/jem.188.2.277. J Exp Med. 1998. PMID: 9670040 Free PMC article.

3

Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations.

Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA. Worley BS, et al. Among authors: goletz tj. Cancer Res. 2001 Sep 15;61(18):6868-75. Cancer Res. 2001. PMID: 11559563

4

Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

Goletz TJ, Klimpel KR, Arora N, Leppla SH, Keith JM, Berzofsky JA. Goletz TJ, et al. Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12059-64. doi: 10.1073/pnas.94.22.12059. Proc Natl Acad Sci U S A. 1997. PMID: 9342362 Free PMC article.

5

Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.

Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL. Dagher R, et al. Among authors: goletz tj. Med Pediatr Oncol. 2002 Mar;38(3):158-64. doi: 10.1002/mpo.1303. Med Pediatr Oncol. 2002. PMID: 11836714 Clinical Trial.

6

Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms.

McDyer JF, Dybul M, Goletz TJ, Kinter AL, Thomas EK, Berzofsky JA, Fauci AS, Seder RA. McDyer JF, et al. Among authors: goletz tj. J Immunol. 1999 Mar 15;162(6):3711-7. J Immunol. 1999. PMID: 10092834

7

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Woo EY, et al. Among authors: goletz tj. Cancer Res. 2001 Jun 15;61(12):4766-72. Cancer Res. 2001. PMID: 11406550

8

Molecular alterations in pediatric sarcomas: potential targets for immunotherapy.

Goletz TJ, Mackall CL, Berzofsky JA, Helman LJ. Goletz TJ, et al. Sarcoma. 1998;2(2):77-87. doi: 10.1080/13577149878037. Sarcoma. 1998. PMID: 18521238 Free PMC article.

9

Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy.

Wong EC, Maher VE, Hines K, Lee J, Carter CS, Goletz T, Kopp W, Mackall CL, Berzofsky J, Read EJ. Wong EC, et al. Cytotherapy. 2001;3(1):19-29. doi: 10.1080/146532401753156377. Cytotherapy. 2001. PMID: 12028840

10

CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent manner.

McDyer JF, Goletz TJ, Thomas E, June CH, Seder RA. McDyer JF, et al. Among authors: goletz tj. J Immunol. 1998 Feb 15;160(4):1701-7. J Immunol. 1998. PMID: 9469427

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters